Blaine Labs, Inc Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contamination
Potential infection risk for vulnerable patients highlights critical quality system considerations
Recall Overview
Blaine Labs, Inc. has issued a voluntary nationwide recall of select lots of antiseptic wound care gel products due to microbial contamination.
Company: Blaine Labs, Inc.
Brand Names: Revitaderm®, Tridergel™
Product Type: Drug (Topical antiseptic)
FDA Publish Date: April 8, 2026
Reason: Presence of Lysinibacillus fusiformis
Affected Products
Affected products were distributed nationwide to healthcare providers (non-retail).
Revitaderm® Wound Care Antiseptic Gel (1 oz. & 3 oz.)
Active Ingredient: Benzalkonium Chloride 0.1%
Affected lots:
- BL3608 (Exp. 07/01/28)
- BL3435 (Exp. 11/06/26)
- BL3525 (Exp. 08/07/27)
Tridergel™ Wound Care (1 oz.)
Active Ingredient: Benzalkonium Chloride 0.1%
Affected lot: BL3435 (Exp. 11/06/26)
Risk Assessment
The contamination involves Lysinibacillus fusiformis, a spore-forming environmental organism. While generally low risk for healthy individuals, the risk profile changes significantly for patients with open wounds, diabetic patients, elderly individuals, and immunocompromised populations.
Potential outcomes include local infection, skin irritation, delayed wound healing, and severe complications (rare), that include endocarditis, a central nervous system infection.
Clinical Context
This recall is particularly notable because the product is intended to prevent infection. Contamination in this context represents a reversal of intended function, increasing risk rather than mitigating it.
MDP Regulatory and Quality Insight
This event highlights several critical areas of concern.
Microbiological Control in Non-Sterile Drug Products
Even though these are non-sterile topical products, they must meet microbial limits and have an absence of objectionable organisms.
The presence of a spore-forming organism suggests potential gaps in environmental control, inadequate preservative effectiveness, and possible manufacturing or packaging contamination pathways.
Risk-Based Product Use Consideration
Topical antiseptics that are used on broken skin or other compromised tissue functionally behave like higher-risk products. This raises the question of whether certain “non-sterile” products be tested with enhanced microbial controls?
Distribution Channel Risk
Products were distributed to physician offices and other clinical settings. This increases risk because product use is likely on vulnerable patient populations where traceability and recall effectiveness become critical.
CAPA and Root Cause Expectations
Regulators will expect a full root cause investigation, to include an evaluation of water systems, raw materials, environmental monitoring, and packaging integrity.
What Healthcare Providers Should Do
Healthcare providers who have these products should immediately identify and segregate affected lots, discontinue use and distribution, and contact Blaine Labs for return instructions.
Adverse Events
To date, no adverse events have been reported. However, given the risk population, monitoring is warranted.
MDP Perspective
This recall underscores a critical principle, that product classification does not always reflect real-world risk. A “non-sterile” topical product that is applied to compromised tissue, especially in vulnerable populations, can present risks closer to those of sterile products if contamination occurs.
Key Takeaways for Manufacturers
Manufacturers of topical products should reevaluate microbial control strategies, strengthen environmental monitoring programs, validate preservative systems rigorously, and consider risk-based escalation of controls for wound care products.
Contact Information
Blaine Labs, Inc.
📞 (800) 307-8818
📧 Contact@blainelabs.com
Links
Read the FDA’s announcement here.
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
FDA Investigates Cancer Risk with Zolgensma Gene Therapy
Postmarketing reports identify cases of tumor formation linked to gene therapy vector integration, prompting FDA to evaluate potential regulatory action.The U.S. Food and Drug Administration (FDA) is investigating a serious potential cancer risk associated with...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Class 1 Recall for HemosIL AcuStar HIT Antibody Test
HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...



